Indivior is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. For more than 25 years, we have revolutionized the science of addiction medicine — developing treatments that help people move toward long-term recovery with independence and dignity.
Our commitment is unwavering: to expand access to effective treatment, dismantle stigma, and empower every person living with OUD to define their lives beyond the disease.
We partner with scientists, communities, clinicians, policymakers, people living with OUD, and caregivers to advance access to evidence-based treatment for OUD, dismantle stigma, and elevate the lived experience of individuals in recovery. Together, we are advancing recovery for OUD — one life, one family, and one community at a time.
Indivior PLC (Nasdaq: INDV) today announced the Company has concluded the legacy U.S. Department of Justice (DOJ) matter by paying in full the outstanding obligation of $295 million associated with the matter.